Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen KJ, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch SD. Sebastian M, et al. Among authors: gnad vogt u. Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15. Cancer Immunol Immunother. 2019. PMID: 30770959 Clinical Trial.
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A. Sebastian M, et al. Among authors: gnad vogt u. BMC Cancer. 2014 Oct 6;14:748. doi: 10.1186/1471-2407-14-748. BMC Cancer. 2014. PMID: 25288198 Free PMC article. Clinical Trial.
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.
Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A. Kübler H, et al. Among authors: gnad vogt u. J Immunother Cancer. 2015 Jun 16;3:26. doi: 10.1186/s40425-015-0068-y. eCollection 2015. J Immunother Cancer. 2015. PMID: 26082837 Free PMC article.
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A. Papachristofilou A, et al. Among authors: gnad vogt u. J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5. J Immunother Cancer. 2019. PMID: 30736848 Free PMC article. Clinical Trial.
Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.
Hong HS, Koch SD, Scheel B, Gnad-Vogt U, Schröder A, Kallen KJ, Wiegand V, Backert L, Kohlbacher O, Hoerr I, Fotin-Mleczek M, Billingsley JM. Hong HS, et al. Among authors: gnad vogt u. Oncoimmunology. 2016 Nov 18;5(12):e1249560. doi: 10.1080/2162402X.2016.1249560. eCollection 2016. Oncoimmunology. 2016. PMID: 28123889 Free PMC article.
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, Fotin-Mleczek M, Hoerr I, Clemens R, von Sonnenburg F. Alberer M, et al. Among authors: gnad vogt u. Lancet. 2017 Sep 23;390(10101):1511-1520. doi: 10.1016/S0140-6736(17)31665-3. Epub 2017 Jul 25. Lancet. 2017. PMID: 28754494 Clinical Trial.
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. Lennerz V, et al. Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2. Cancer Immunol Immunother. 2014. PMID: 24487961 Free article. Clinical Trial.
NSCLC - immunogenic after all?
Kallen KJ, Gnad-Vogt U. Kallen KJ, et al. J Thorac Dis. 2011 Jun;3(2):79-81. doi: 10.3978/j.issn.2072-1439.2011.02.01. J Thorac Dis. 2011. PMID: 22263067 Free PMC article. No abstract available.
Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.
Gross S, Lennerz V, Gallerani E, Mach N, Böhm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Forssmann U, Woelfel T, Kaempgen E. Gross S, et al. Among authors: gnad vogt u. Cancer Immunol Res. 2016 Jan;4(1):18-25. doi: 10.1158/2326-6066.CIR-15-0105. Epub 2015 Nov 12. Cancer Immunol Res. 2016. PMID: 26563311 Clinical Trial.
16 results